Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours

@article{Kashyap2014FavourableOO,
  title={Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours},
  author={Raghava Kashyap and Michael S Hofman and Michael Michael and Grace Kong and Timothy Akhurst and Peter Eu and Diana Zannino and Rodney J Hicks},
  journal={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2014},
  volume={42},
  pages={176-185}
}
Increased glycolytic activity on FDG PET/CT defines a subgroup of patients with metastatic gastroenteropancreatic neuroendocrine tumour (NET) with a poor prognosis. A limited range of systemic treatment options exist for more aggressive NET. The role of peptide receptor chemoradionuclide therapy (PRCRT) in such patients is, however, unclear. This retrospective study assessed the outcomes of patients with FDG-avid NET treated with PRCRT. Clinical, biochemical and imaging response was assessed… CONTINUE READING